Standardization study of Sjogren's syndrome based on epidemiological investigation and cohort study

注册号:

Registration number:

ITMCTR1900002438

最近更新日期:

Date of Last Refreshed on:

2019-07-03

注册时间:

Date of Registration:

2019-07-03

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于流行病学调查与队列研究开展干燥综合征的规范化研究

Public title:

Standardization study of Sjogren's syndrome based on epidemiological investigation and cohort study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于流行病学调查与队列研究开展干燥综合征的规范化研究

Scientific title:

Standardization study of Sjogren's syndrome based on epidemiological investigation and cohort study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900024263 ; ChiMCTR1900002438

申请注册联系人:

张欢

研究负责人:

吴斌

Applicant:

Zhang Huan

Study leader:

Wu Bin

申请注册联系人电话:

Applicant telephone:

+86 15581668459

研究负责人电话:

Study leader's telephone:

+86 15086705783

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

269789275@qq.com

研究负责人电子邮件:

Study leader's E-mail:

wuubinn@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

重庆市江北区盘溪七支路6号

研究负责人通讯地址:

重庆市江北区盘溪七支路6号

Applicant address:

6 Panxi Qizhi Road, Jiangbei District, Chongqing, China

Study leader's address:

6 Panxi Qizhi Road, Jiangbei District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆市中医院

Applicant's institution:

Chongqing Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2019-KY-KS-3

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

重庆市中医院伦理委员会

Name of the ethic committee:

Ethics committee of Chongqing Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2019/3/8 0:00:00

伦理委员会联系人:

魏知

Contact Name of the ethic committee:

Wei Zhi

伦理委员会联系地址:

重庆市江北区盘溪七支路6号

Contact Address of the ethic committee:

6 Panxi Qizhi Road, Jiangbei District, Chongqing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆市中医院

Primary sponsor:

Chongqing Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

重庆市江北区盘溪七支路6号

Primary sponsor's address:

6 Panxi Qizhi Road, Jiangbei District, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆市中医院

具体地址:

重庆市江北区盘溪七支路6号

Institution
hospital:

Chongqing Hospital of Traditional Chinese Medicine

Address:

6 Panxi Qizhi Road, Jiangbei District, Chongqing, China

经费或物资来源:

重庆市卫生计生委中医药科技项目

Source(s) of funding:

Chongqing Municipal Health and Family Planning Commission Chinese Medicine Science and Technology Project

研究疾病:

干燥综合征

研究疾病代码:

Target disease:

Sjogren's syndrome

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

单臂

Single arm

研究所处阶段:

Study phase:

其它

Others

研究目的:

获取干燥综合征的患病率、危险因素;获取中医证候分布规律及核心要素;采用队列研究评价中医药治疗的疗效。

Objectives of Study:

Obtaining the prevalence and risk factors of Sjogren's syndrome; obtaining the distribution rules and core elements of TCM syndromes; evaluating the curative effect of TCM treatment by cohort study.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.符合西医诊断标准;2.符合中医诊断标准;3.年龄18~65周岁;4.签署知情同意书。

Inclusion criteria

1. Meet the diagnostic criteria of Western medicine; 2. Meet the diagnostic criteria of Chinese medicine; 3. Aged 18 to 65 years old; 4. Sign the informed consent form.

排除标准:

流行病学调查:1.其他结缔组织病、淋巴瘤、艾滋病、结节病、移植物抗宿主病、晚期的淋巴组织增生;2.精神病患者等无法合作者。

Exclusion criteria:

Epidemiological Investigation1: 1. Other connective tissue diseases, lymphoma, AIDS, sarcoidosis, graft-versus-host disease, advanced lymphoid tissue hyperplasia; 2. Psychiatric patients and other uncooperative.

研究实施时间:

Study execute time:

From 2019-03-09

To      2023-12-31

征募观察对象时间:

Recruiting time:

From 2019-07-10

To      2020-10-01

干预措施:

Interventions:

组别:

Case series

样本量:

200

Group:

Case series

Sample size:

干预措施:

中药

干预措施代码:

Intervention:

Chinese medicine

Intervention code:

样本总量 Total sample size : 30000

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆市中医院

单位级别:

三甲医院

Institution/hospital:

Chongqing Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

免疫球蛋白

指标类型:

次要指标

Outcome:

Immunoglobulin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血沉

指标类型:

次要指标

Outcome:

ESR

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

泪液分泌

指标类型:

次要指标

Outcome:

Schirmer test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

危险因素

指标类型:

次要指标

Outcome:

Risk factor

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

口干调查表

指标类型:

主要指标

Outcome:

Dry mouth questionnaire

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ESSPRI评分

指标类型:

次要指标

Outcome:

ESSPRI score sheet

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

次要指标

Outcome:

CRP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ESSDAI评分

指标类型:

次要指标

Outcome:

ESSDAI score sheet

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候量表

指标类型:

主要指标

Outcome:

TCM syndrome scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

人口学资料

指标类型:

次要指标

Outcome:

Demographic data

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼干调查表

指标类型:

主要指标

Outcome:

Eye dryness questionnaire

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

唾液流率

指标类型:

次要指标

Outcome:

Salivary flow rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

唾液

组织:

Sample Name:

saliva

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

泪液

组织:

Sample Name:

Tears

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 16
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

流行病学调查:将全市38个县级行政区划单位进行编号,随机选择15个县区,再根据选择的县区将其居(村)民委员会编号后随机选择1个,每个调查点调查2000人,合计调查30000人。

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024年6月,如需资料请联系项目负责人

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

In June 2024. Please contact the project leader if you need information.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集使用纸质问卷、问卷星和epidata等方法,管理使用epidata和SPSS等软件。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection uses paper questionnaires, questionnaire stars, and epidata etc. and management software such as epidata and SPSS.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above